These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

323 related items for PubMed ID: 10463598

  • 1. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB, Sharma SK, Boxer GM, Boden R, Stribbling SM, Davies L, Springer CJ, Begent RH.
    Cancer Res; 1999 Aug 15; 59(16):3998-4003. PubMed ID: 10463598
    [Abstract] [Full Text] [Related]

  • 2. ZD2767, an improved system for antibody-directed enzyme prodrug therapy that results in tumor regressions in colorectal tumor xenografts.
    Blakey DC, Burke PJ, Davies DH, Dowell RI, East SJ, Eckersley KP, Fitton JE, McDaid J, Melton RG, Niculescu-Duvaz IA, Pinder PE, Sharma SK, Wright AF, Springer CJ.
    Cancer Res; 1996 Jul 15; 56(14):3287-92. PubMed ID: 8764123
    [Abstract] [Full Text] [Related]

  • 3. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
    Pedley RB, Boden JA, Boden R, Boxer GM, Flynn AA, Keep PA, Begent RH.
    Cancer Res; 1996 Jul 15; 56(14):3293-300. PubMed ID: 8764124
    [Abstract] [Full Text] [Related]

  • 4. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RH.
    Clin Cancer Res; 2000 Mar 15; 6(3):765-72. PubMed ID: 10741695
    [Abstract] [Full Text] [Related]

  • 5. Antibody directed enzyme prodrug therapy (ADEPT): clinical report.
    Bagshawe KD, Sharma SK, Springer CJ, Antoniw P, Boden JA, Rogers GT, Burke PJ, Melton RG, Sherwood RF.
    Dis Markers; 1991 Mar 15; 9(3-4):233-8. PubMed ID: 1813213
    [Abstract] [Full Text] [Related]

  • 6. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM, Martin J, Pedley RB, Boden JA, Sharma SK, Springer CJ.
    Cancer Chemother Pharmacol; 1997 Mar 15; 40(4):277-84. PubMed ID: 9225945
    [Abstract] [Full Text] [Related]

  • 7. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC, Davies DH, Dowell RI, East SJ, Burke PJ, Sharma SK, Springer CJ, Mauger AB, Melton RG.
    Br J Cancer; 1995 Nov 15; 72(5):1083-8. PubMed ID: 7577451
    [Abstract] [Full Text] [Related]

  • 8. Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models.
    Friedlos F, Davies L, Scanlon I, Ogilvie LM, Martin J, Stribbling SM, Spooner RA, Niculescu-Duvaz I, Marais R, Springer CJ.
    Cancer Res; 2002 Mar 15; 62(6):1724-9. PubMed ID: 11912146
    [Abstract] [Full Text] [Related]

  • 9. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD, Francis RJ, Pedley RB, Sharma SK, Begent RH, Hartley JA, Hochhauser D.
    Br J Cancer; 2001 Jun 15; 84(12):1671-6. PubMed ID: 11401322
    [Abstract] [Full Text] [Related]

  • 10. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A, Francis RJ, Sharma SK, Tolner B, Springer CJ, Martin J, Boxer GM, Bell J, Green AJ, Hartley JA, Cruickshank C, Wren J, Chester KA, Begent RH.
    Clin Cancer Res; 2006 Nov 01; 12(21):6509-16. PubMed ID: 17085666
    [Abstract] [Full Text] [Related]

  • 11. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC, Valcaccia BE, East S, Wright AF, Boyle FT, Springer CJ, Burke PJ, Melton RG, Bagshawe KD.
    Cell Biophys; 1993 Nov 01; 22(1-3):1-8. PubMed ID: 7889535
    [Abstract] [Full Text] [Related]

  • 12. Antibody directed enzyme prodrug therapy (ADEPT): a three phase system.
    Sharma SK, Bagshawe KD, Springer CJ, Burke PJ, Rogers GT, Boden JA, Antoniw P, Melton RG, Sherwood RF.
    Dis Markers; 1991 Nov 01; 9(3-4):225-31. PubMed ID: 1813212
    [Abstract] [Full Text] [Related]

  • 13. Regression of established breast carcinoma xenografts with antibody-directed enzyme prodrug therapy against c-erbB2 p185.
    Eccles SA, Court WJ, Box GA, Dean CJ, Melton RG, Springer CJ.
    Cancer Res; 1994 Oct 01; 54(19):5171-7. PubMed ID: 7923136
    [Abstract] [Full Text] [Related]

  • 14. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethyl-benzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT).
    Springer CJ, Antoniw P, Bagshawe KD, Wilman DE.
    Anticancer Drug Des; 1991 Nov 01; 6(5):467-79. PubMed ID: 1764165
    [Abstract] [Full Text] [Related]

  • 15. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.
    Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH.
    Cancer Res; 2001 Jun 15; 61(12):4716-22. PubMed ID: 11406542
    [Abstract] [Full Text] [Related]

  • 16. Self-immolative nitrogen mustard prodrugs for suicide gene therapy.
    Niculescu-Duvaz D, Niculescu-Duvaz I, Friedlos F, Martin J, Spooner R, Davies L, Marais R, Springer CJ.
    J Med Chem; 1998 Dec 17; 41(26):5297-309. PubMed ID: 9857097
    [Abstract] [Full Text] [Related]

  • 17. Antibody-directed enzyme prodrug therapy: pharmacokinetics and plasma levels of prodrug and drug in a phase I clinical trial.
    Martin J, Stribbling SM, Poon GK, Begent RH, Napier M, Sharma SK, Springer CJ.
    Cancer Chemother Pharmacol; 1997 Dec 17; 40(3):189-201. PubMed ID: 9219501
    [Abstract] [Full Text] [Related]

  • 18. Antibody-directed enzyme prodrug therapy (ADEPT) with mustard prodrugs.
    Springer CJ, Niculescu-Duvaz I.
    Anticancer Drug Des; 1995 Jul 17; 10(5):361-72. PubMed ID: 7639927
    [Abstract] [Full Text] [Related]

  • 19. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL, Jungheim LN, Law KL, Mikolajczyk SD, Shepherd TA, Mackensen DG, Briggs SL, Starling JJ.
    Cancer Res; 1993 Sep 01; 53(17):3956-63. PubMed ID: 8358723
    [Abstract] [Full Text] [Related]

  • 20. Induction of apoptosis by the ADEPT agent ZD2767: comparison with the classical nitrogen mustard chlorambucil and a monofunctional ZD2767 analogue.
    Monks NR, Blakey DC, Curtin NJ, East SJ, Heuze A, Newell DR.
    Br J Cancer; 2001 Sep 01; 85(5):764-71. PubMed ID: 11531265
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.